0.60
+4.98%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biomea Fusion
From its filings with the US Securities and Exchange Commission
Biomea Fusion is based in San Carlos, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BMEA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $61.8m. At that date it held total assets of $58.6m and shareholders' equity of $29.6m.
We are a clinical‑stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases.
The company was founded in 2017 with the goal of creating targeted treatments built through expertise in chemistry and a deep understanding of metabolic biology. Following the strategic realignment announced in 2025, we now operate as an organization centered on two of our core drug candidate development programs: (i) icovamenib, our lead clinical program’s drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, our investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist (GLP-1 RA) in development for the treatment of obesity.
Today, we have approximately 40 employees and a streamlined operating structure that we believe emphasizes capital efficiency, scientific discipline and focused execution. Our research and development functions are supported by integrated clinical development, clinical operations, clinical pharmacology, regulatory affairs, pharmacovigilance and quality functions.
Quoted from its 10-K, filed 24 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Apr 2021
- Employees
- 103
- Website
- biomeafusion.com ↗
- Head office
- 1599 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Rainer ErdtmannPresident, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director, since 2017$2.0m
- Dr. Michael HitchcockInterim Chief Executive Officer, Director, since 2021$241,496
- Dr. Juan FrasChief Medical Officer, Head of Diabetes$3.9m
- Dr. Eric AguiarLead Independent Director$254,996
- Ms. Julianne AverillIndependent Director
- Dr. Elizabeth FaustIndependent Director$223,996
- Ms. Sumita RayIndependent Director$235,496
- Ms. Meichiel Jennifer WeissSenior Director, Investor Relations and Corporate Development, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 30
- Environment
- 31
- Social
- 39
- Governance
- 20
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biomea Fusion Inc employs 103 full-time employees focused on hematological oncology biopharmaceuticals.
- The FUSION System discovery platform advances covalent small molecule product candidates for genetically defined cancers.
- BMF-219 is an orally bioavailable covalent inhibitor targeting menin in oncogenic signaling for leukemias.
Weaknesses
- Biomea Fusion Inc has a small workforce of 103 employees in the competitive biotechnology sector.
- The company's lead product BMF-219 is still in development for leukemias with MLL fusion protein.
- Biomea Fusion Inc's IPO on 16 April 2021 shows limited market presence.
Opportunities
- The FUSION System platform could expand to treat additional genetically defined cancers beyond leukemias.
- BMF-219 may address unmet needs in liquid and solid tumors dependent on menin.
- Biomea Fusion Inc could leverage its covalent small molecule expertise for new therapeutic areas.
Threats
- Biomea Fusion Inc faces competition from established biopharmaceutical companies in hematological oncology.
- The development of BMF-219 could encounter clinical trial delays or failures.
- Regulatory approval for BMF-219 may be challenging in the US market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.